Abbott announces the launch of its TactiFlex, Sensor Enabled ablation catheter, the world’s first ablation catheter with a flexible tip and contact force technology. Used for ablation procedures to treat atrial fibrillation (AF), the most common abnormal heart rhythm, the TactiFlex™ catheter can reduce procedure time 1 and improve safety compared to the company’s previous generation catheters 2 .
More than 37 million people worldwide live with atrial fibrillation 3 and the numbers are expected to more than double by 2050 4 . Another five million 5 cases are diagnosed each year, indicating a growing healthcare challenge that demands innovative solutions for patients and their doctors. In Brazil, estimates indicate that up to 5 million people have the disease – without even knowing it. In practice, one in three people hospitalized with cardiac arrhythmia has atrial fibrillation. Among the elderly, the situation is even more critical. On average, 10% of people over 70 years of age have this health problem 6 .
For those who suffer from atrial fibrillation, daily life can be challenging as people often experience dizziness, chest pain, and heart palpitations. Furthermore, it can lead to a stroke if left untreated, which makes it even more critical that it be treated as soon as possible.
“We are entering a new era of ablation procedures for atrial fibrillation due to new technologies developed, such as Abbott’s flexible tip contact force catheter, the TactiFlex. This new catheter along with cutting-edge equipment for mapping arrhythmias cardiac devices, EnSite
Also Read : Shimadzu Medical Systems USA installs first TRINIAS SCORE OPERA Cardiac Catheterization Lab in the US
New catheters and other cutting-edge solutions from Abbott for patients with atrial fibrillation
Unlike other catheters available on the market, TactiFlex™ uses an innovative design with a laser-cut pattern that flexes when in contact with the heart wall. This helps direct fluid to the treated tissue 1 and allows for more precise catheter positioning – providing twice the stability in a beating heart – for consistent therapy delivery 7 .
“Abbott, being the company with the most complete portfolio for the treatment of cardiac arrhythmias, has been leading this market with the new technologies developed. The EnSite X Electrophysiology System together with the TactiFlex catheter, allow doctors and patients to feel even more confident that ablation procedures will provide increasingly safe and effective results,” concludes Letícia.
SOURCE : PRNewswire